4/11
10:09 am
ocup
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]
Medium
Report
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery [Yahoo! Finance]
4/11
10:03 am
ocup
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Medium
Report
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
4/1
07:14 am
ocup
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
High
Report
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
3/20
08:32 am
ocup
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
3/13
07:16 am
ocup
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
Medium
Report
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]
3/10
10:11 am
ocup
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
3/8
08:00 am
ocup
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
High
Report
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
2/23
08:08 am
ocup
Ocuphire Pharma to Present in the BIO CEO & Investor Conference [Yahoo! Finance]
Neutral
Report
Ocuphire Pharma to Present in the BIO CEO & Investor Conference [Yahoo! Finance]
2/23
08:00 am
ocup
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Low
Report
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
2/15
04:10 pm
ocup
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/14
08:10 am
ocup
Ocuphire Pharma Strengthens Leadership Team with Key Appointments [Yahoo! Finance]
Low
Report
Ocuphire Pharma Strengthens Leadership Team with Key Appointments [Yahoo! Finance]
2/14
08:00 am
ocup
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Low
Report
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
2/5
08:12 am
ocup
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference [Yahoo! Finance]
Medium
Report
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference [Yahoo! Finance]
2/5
08:00 am
ocup
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Medium
Report
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
1/24
04:13 pm
ocup
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/24
04:10 pm
ocup
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/24
11:04 am
ocup
Night Vision Disturbance Market Poised for Growth, Driven by Emerging Therapies and Increasing Diagnosed Prevalence [Yahoo! Finance]
Low
Report
Night Vision Disturbance Market Poised for Growth, Driven by Emerging Therapies and Increasing Diagnosed Prevalence [Yahoo! Finance]